Hemogenyx Pharmaceuticals (LON:HEMO) Trading Up 1.6% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares were up 1.6% during mid-day trading on Thursday . The company traded as high as GBX 699 and last traded at GBX 680. Approximately 8,701 shares were traded during trading, a decline of 71% from the average daily volume of 29,849 shares. The stock had previously closed at GBX 669.

Hemogenyx Pharmaceuticals Price Performance

The business has a fifty day moving average of GBX 861.77 and a 200-day moving average of GBX 804.01. The firm has a market cap of £44.33 million, a PE ratio of -4.04 and a beta of 1.54. The company has a current ratio of 1.38, a quick ratio of 6.72 and a debt-to-equity ratio of 167.66.

Hemogenyx Pharmaceuticals (LON:HEMO) last issued its quarterly earnings data on Thursday, April 30th. The company reported GBX (170.60) earnings per share (EPS) for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.